Abstract
Introduction: FIRE3 compared 1st-line therapy with FOLFIRI plus either cetuximab (arm A) or bevacizumab (arm B) in 592 patients with KRAS exon 2 wild-type mCRC. We investigated choice and duration of 2nd-line therapies according to 1st-line efficacy as well as overall survival (OS) and OS from beginning of 2nd-line therapy according to 2nd-line treatment.